| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Saturday, May 31, 2014 10:47:39 AM
Pharma dude..
Re the short position.
The Amarin short position must be understood in terms of the Jan 9 2012 converible notes issue.
"The notes will be exchangeable prior to October 15, 2031 only under certain circumstances and during certain periods, and will be exchangeable thereafter regardless of those circumstances. The exchange rate will initially be 113.4752 American Depositary Shares of Amarin ("ADS") per $1,000 principal amount of the notes (equivalent to an initial exchange price of approximately $8.81 per ADS), subject to adjustment in certain circumstances. The initial exchange rate for the notes represents an approximately 25% exchange premium over the last reported sale price of the ADSs on January 3, 2012, which was $7.05 per ADS. Upon exchange, the notes may be settled, at the Issuer's election, in cash, ADS or a combination of cash and ADS.
The notes will accrue interest at an annual rate of 3.5%.
To understand the "short position" you have to understand that these "convertible (into common) notes were not redeemable before 2017 except under very specific circumstances. Also these notes were drawing 3.5% annual interest at $8.81 per bond. These notes were only sold to "qualified buyers (banks, funds, etc.).
These conditions set up a compelling hedge. The buyer simply has to short 113 AMRN shares for every $1000 worth of notes he holds. This sets up a neutral stock position, you are essentially "selling short against the box" You get your $8.80 (the cost of the note) back on the short sale and end up making 3.5% annual on principal amount of notes you still hold. The only cost being the money required to secure your short position. This is very little if you are a bank or a fund.
Basically everyone who bought the convertible followed this hedge. This results in over 15 MIL SHARES that are being shorted, not by guys betting on the stock going down, but by big players taking advantage of very cheap money. In these hedged shorts there is no danger of a short squeeze because they are hedged by owning the convertible.
":>) JL
Re the short position.
The Amarin short position must be understood in terms of the Jan 9 2012 converible notes issue.
"The notes will be exchangeable prior to October 15, 2031 only under certain circumstances and during certain periods, and will be exchangeable thereafter regardless of those circumstances. The exchange rate will initially be 113.4752 American Depositary Shares of Amarin ("ADS") per $1,000 principal amount of the notes (equivalent to an initial exchange price of approximately $8.81 per ADS), subject to adjustment in certain circumstances. The initial exchange rate for the notes represents an approximately 25% exchange premium over the last reported sale price of the ADSs on January 3, 2012, which was $7.05 per ADS. Upon exchange, the notes may be settled, at the Issuer's election, in cash, ADS or a combination of cash and ADS.
The notes will accrue interest at an annual rate of 3.5%.
To understand the "short position" you have to understand that these "convertible (into common) notes were not redeemable before 2017 except under very specific circumstances. Also these notes were drawing 3.5% annual interest at $8.81 per bond. These notes were only sold to "qualified buyers (banks, funds, etc.).
These conditions set up a compelling hedge. The buyer simply has to short 113 AMRN shares for every $1000 worth of notes he holds. This sets up a neutral stock position, you are essentially "selling short against the box" You get your $8.80 (the cost of the note) back on the short sale and end up making 3.5% annual on principal amount of notes you still hold. The only cost being the money required to secure your short position. This is very little if you are a bank or a fund.
Basically everyone who bought the convertible followed this hedge. This results in over 15 MIL SHARES that are being shorted, not by guys betting on the stock going down, but by big players taking advantage of very cheap money. In these hedged shorts there is no danger of a short squeeze because they are hedged by owning the convertible.
":>) JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
